# Maxim Group

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/maxim-group
Canonical HTML page: https://getbiobrief.com/entity/maxim-group

## Timeline

- **2026-08-14**: Silexion reports quarterly results — Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
- **2026-07-29**: Maxim Group downgrades to Hold — Maxim Group lowered Silexion Therapeutics from a Strong-Buy rating to a Hold rating.
- **2026-06-15**: Weiss Ratings reiterates Sell (E+) — Weiss Ratings reiterated a Sell (E+) rating on Silexion Therapeutics shares.

## Recent coverage (2 stories)

### SLXN's RNAi Pipeline Faces $0.42 Stock and $5.17 EPS Loss
2026-08-16 15:01:58 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Full story: https://getbiobrief.com/story/silexion-rnai-pipeline-earnings

### Insider Buys 7,736 HCWB Shares at $2.58; Stock 93% Below 52-Week High
2026-08-12 20:23:40 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A corporate insider at microcap HCW Biologics disclosed a $19,958.88 purchase of 7,736 shares at $2.58, but conflicting syndicated reports name different insiders. For biotech investors, the transaction highlights a high-risk stock trading 93% below its 52-week high despite a May EPS beat and a $30 Maxim target.
Full story: https://getbiobrief.com/story/hcwb-insider-buy-7736-shares-biotech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.